Showing 6981-6990 of 9098 results for "".
- Actavis Announces Acanya Gel Patent Challenge Settlementhttps://practicaldermatology.com/news/20140512-actavis_announces_acanya_gel_patent_challenge_settlement/2459243/
- 2014 AAD Election Resultshttps://practicaldermatology.com/news/20140424-2014_aad_election_results/2459257/
- Nuvo Research Announces Collaboration to Develop Topical Dermatology Productshttps://practicaldermatology.com/news/20140423-nuvo_research_announces_collaboration_to_develop_topical_dermatology_products/2459258/Nuvo Research Inc. is collaborating with Ferndale Laboratories, Inc. and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexe
- Phase 3 Results Promising for Oral Psoriasis Agenthttps://practicaldermatology.com/news/20140422-phase_3_results_promising_for_oral_psoriasis_agent/2459260/Results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program indicate that the investigational oral Janus kinase (JAK) inhibitor tofacitinib (Pfizer) is both safe and effective for patients with moderate to severe psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 stu
- Modernizing Medicine Named SIIA Software CODiE Award Finalist for Best Healthcare IT Solutionhttps://practicaldermatology.com/news/20140404-modernizing_medicine_named_siia_software_codie_award_finalist_for_best_healthcare_it_solution/2459278/
- Merz North America Introduces Mederma PMhttps://practicaldermatology.com/news/20140331-merz_north_america_introduces_mederma_pm/2459290/
- Restoration Robotics Launches ARTAS Robotic System For Hair Restorationhttps://practicaldermatology.com/news/20140326-restoration_robotics_launches_artas_robotic_system_for_hair_restoration/2459294/
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- Zeltiq® Aesthetics Launches CoolSmooth™ Applicatorhttps://practicaldermatology.com/news/20140321-zeltiq_aesthetics_launches_coolsmooth_applicator/2459304/
- Sciton Announces Launch of Halo at AAD Annual Meetinghttps://practicaldermatology.com/news/20140320-sciton_announces_launch_of_halo_at_aad_annual_meeting/2459309/